International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease - PubMed (original) (raw)
Review
. 2018 Aug;33(8):1248-1266.
doi: 10.1002/mds.27372. Epub 2018 Mar 23.
Affiliations
- PMID: 29570866
- DOI: 10.1002/mds.27372
Review
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
Susan H Fox et al. Mov Disord. 2018 Aug.
Erratum in
- Erratum.
[No authors listed] [No authors listed] Mov Disord. 2018 Dec;33(12):1992. doi: 10.1002/mds.27548. Epub 2018 Oct 30. Mov Disord. 2018. PMID: 30578695 No abstract available.
Abstract
Objective: The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's disease (PD).
Background: The Movement Disorder Society Evidence-Based Medicine Committee recommendations for treatments of PD were first published in 2002 and updated in 2011, and we continued the review to December 31, 2016.
Methods: Level I studies of interventions for motor symptoms were reviewed. Criteria for inclusion and quality scoring were as previously reported. Five clinical indications were considered, and conclusions regarding the implications for clinical practice are reported.
Results: A total of 143 new studies qualified. There are no clinically useful interventions to prevent/delay disease progression. For monotherapy of early PD, nonergot dopamine agonists, oral levodopa preparations, selegiline, and rasagiline are clinically useful. For adjunct therapy in early/stable PD, nonergot dopamine agonists, rasagiline, and zonisamide are clinically useful. For adjunct therapy in optimized PD for general or specific motor symptoms including gait, rivastigmine is possibly useful and physiotherapy is clinically useful; exercise-based movement strategy training and formalized patterned exercises are possibly useful. There are no new studies and no changes in the conclusions for the prevention/delay of motor complications. For treating motor fluctuations, most nonergot dopamine agonists, pergolide, levodopa ER, levodopa intestinal infusion, entacapone, opicapone, rasagiline, zonisamide, safinamide, and bilateral STN and GPi DBS are clinically useful. For dyskinesia, amantadine, clozapine, and bilateral STN DBS and GPi DBS are clinically useful.
Conclusions: The options for treating PD symptoms continues to expand. These recommendations allow the treating physician to determine which intervention to recommend to an individual patient. © 2018 International Parkinson and Movement Disorder Society.
Keywords: Parkinson's disease; amantadine; anticholinergics; catechol-O-methyl transferase inhibitors; clozapine; complementary therapies; deep brain stimulation; dopamine agonists; evidence-based medicine; exercise; levodopa; monoamine oxidase inhibitors; neurosurgery; occupational therapy; physical therapy; randomized controlled trial; speech therapy.
© 2018 International Parkinson and Movement Disorder Society.
Similar articles
- The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.
Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C. Fox SH, et al. Mov Disord. 2011 Oct;26 Suppl 3:S2-41. doi: 10.1002/mds.23829. Mov Disord. 2011. PMID: 22021173 Review. - The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. Seppi K, et al. Mov Disord. 2011 Oct;26 Suppl 3(0 3):S42-80. doi: 10.1002/mds.23884. Mov Disord. 2011. PMID: 22021174 Free PMC article. Review. - Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Oertel W, Schulz JB. Oertel W, et al. J Neurochem. 2016 Oct;139 Suppl 1:325-337. doi: 10.1111/jnc.13750. Epub 2016 Aug 30. J Neurochem. 2016. PMID: 27577098 Review. - Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Goetz CG, Poewe W, Rascol O, Sampaio C. Goetz CG, et al. Mov Disord. 2005 May;20(5):523-39. doi: 10.1002/mds.20464. Mov Disord. 2005. PMID: 15818599 Review. - Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J, Stacy M. Jankovic J, et al. CNS Drugs. 2007;21(8):677-92. doi: 10.2165/00023210-200721080-00005. CNS Drugs. 2007. PMID: 17630819 Review.
Cited by
- Update on the application of mesenchymal stem cell-derived exosomes in the treatment of Parkinson's disease: A systematic review.
Liu SF, Li LY, Zhuang JL, Li MM, Ye LC, Chen XR, Lin S, Chen CN. Liu SF, et al. Front Neurol. 2022 Oct 3;13:950715. doi: 10.3389/fneur.2022.950715. eCollection 2022. Front Neurol. 2022. PMID: 36262830 Free PMC article. Review. - Deep Brain Stimulation in the Treatment of Parkinson's Disease.
Shah H, Usman O, Ur Rehman H, Jhaveri S, Avanthika C, Hussain K, Islam H, I S K S. Shah H, et al. Cureus. 2022 Sep 3;14(9):e28760. doi: 10.7759/cureus.28760. eCollection 2022 Sep. Cureus. 2022. PMID: 36211107 Free PMC article. Review. - Neuroprotective properties of the Lilium brownii extracts in the experimental model of Parkinson's disease.
Hui C, Jin J, Ji M, Wang H, Wang X, Ma J, Wang Y, Si Y, Chen S, Guo T. Hui C, et al. Metab Brain Dis. 2024 Aug;39(6):1085-1097. doi: 10.1007/s11011-024-01397-6. Epub 2024 Jul 26. Metab Brain Dis. 2024. PMID: 39060803 - Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson's Disease.
Jing XZ, Yang HJ, Taximaimaiti R, Wang XP. Jing XZ, et al. Curr Neuropharmacol. 2023;21(5):1224-1240. doi: 10.2174/1570159X20666220915091022. Curr Neuropharmacol. 2023. PMID: 36111769 Free PMC article. Review. - Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.
Rinaldi D, Alborghetti M, Bianchini E, Sforza M, Galli S, Pontieri FE. Rinaldi D, et al. Curr Neuropharmacol. 2023;21(5):1214-1223. doi: 10.2174/1570159X20666220905102144. Curr Neuropharmacol. 2023. PMID: 36065929 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical